Document is current

Article History

Received: 13 September 2021

Accepted: 2 March 2022

First Online: 19 March 2022

Declarations

:

: Our study has been performed in accordance with the Declaration of Helsinki and data collection of the TRANSIT-Stroke network has been approved by the Ethic Committee of the University of Würzburg (Ethikkomission der Universität Würzburg); reference number: 54/14 and was registered in the German Registry for Clinical Studies (DRKS): (registration number: 11696; registration date: 11/08/2017). All patients or their legal representatives provided written informed consent to participate. Data collection of the FC was anonymous and, therefore, no dedicated written informed consent was collected. Data collection procedures were approved by data protection officer.

: Not applicable. The study does not contain individual data.

: KGH reports a study grant by Bayer, lecture fees/advisory board fees from Abbott, Alexion, Amarin, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Pfizer, Premier Research, Portola, Sanofi, SUN Pharma and W. L. Gore & Associates. PK reports a research grant by Daiichi Sankyo and lecture fees from Daiichi Sankyo and Pfizer.PUH reports research grants from German Ministry of Research and Education, European Union, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationfond, German Research Foundation, Bavarian State (ministry for science and the arts), German Cancer Aid, Charité–Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), grants from University Göttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), grants from University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work.HS reports study grants by Bayer, Portola, Alfried Krupp Krankenhaus and Bristol-Myers-Squibb (ODEA-TIA Study), University Göttingen (within FIND-AF randomized, supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime, supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), lecture fees from Bayer, BMS, Daiichi Sankyo.All other authors do not declare any competing interest.